JP2024522350A - 転写状態およびタンパク質組織像の共マッピング - Google Patents

転写状態およびタンパク質組織像の共マッピング Download PDF

Info

Publication number
JP2024522350A
JP2024522350A JP2023573328A JP2023573328A JP2024522350A JP 2024522350 A JP2024522350 A JP 2024522350A JP 2023573328 A JP2023573328 A JP 2023573328A JP 2023573328 A JP2023573328 A JP 2023573328A JP 2024522350 A JP2024522350 A JP 2024522350A
Authority
JP
Japan
Prior art keywords
cells
oligonucleotide probe
disease
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522350A5 (cg-RX-API-DMAC7.html
Inventor
ワン，シャオ
ゼン，フー
レン，ジンイー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute
Original Assignee
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute filed Critical Broad Institute
Publication of JP2024522350A publication Critical patent/JP2024522350A/ja
Publication of JP2024522350A5 publication Critical patent/JP2024522350A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/125—Rolling circle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/162—Helper probe
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023573328A 2021-05-28 2022-05-27 転写状態およびタンパク質組織像の共マッピング Pending JP2024522350A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194536P 2021-05-28 2021-05-28
US63/194,536 2021-05-28
PCT/US2022/031275 WO2022251586A1 (en) 2021-05-28 2022-05-27 Co-mapping transcriptional states and protein histology

Publications (2)

Publication Number Publication Date
JP2024522350A true JP2024522350A (ja) 2024-06-18
JP2024522350A5 JP2024522350A5 (cg-RX-API-DMAC7.html) 2025-06-03

Family

ID=82321599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573328A Pending JP2024522350A (ja) 2021-05-28 2022-05-27 転写状態およびタンパク質組織像の共マッピング

Country Status (9)

Country Link
US (1) US20240376530A1 (cg-RX-API-DMAC7.html)
EP (2) EP4347878B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522350A (cg-RX-API-DMAC7.html)
KR (1) KR20240014486A (cg-RX-API-DMAC7.html)
CN (1) CN117813395A (cg-RX-API-DMAC7.html)
AU (1) AU2022281407A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219339A1 (cg-RX-API-DMAC7.html)
IL (1) IL308570A (cg-RX-API-DMAC7.html)
WO (1) WO2022251586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112243463B (zh) 2018-04-09 2024-12-13 小利兰·斯坦福大学托管委员会 原位基因测序方法
US12497651B2 (en) 2020-11-23 2025-12-16 Pleno, Inc. Encoded dual-probe endonuclease assays
EP4738279A3 (en) 2021-02-19 2026-05-13 The Broad Institute Inc. Multi-scale spatial transcriptomics analysis
EP4334471A1 (en) 2021-05-07 2024-03-13 The Broad Institute Inc. Spatiotemporally resolved transcriptomics at subcellular resolution
DE102022131444A1 (de) * 2022-11-28 2024-05-29 Carl Zeiss Microscopy Gmbh Verfahren zum Identifizieren von Analyten in einer Bildfolge
CN116189880A (zh) * 2023-01-21 2023-05-30 中国医学科学院北京协和医院 一种肺腺癌脑转移的预测指标及预测方法和应用
WO2025136916A1 (en) 2023-12-18 2025-06-26 The Board Institute, Inc. Thick tissue transcriptomics and translatomics
WO2025189030A1 (en) 2024-03-07 2025-09-12 Stellaromics, Inc. Methods and systems for volumetric imaging
CN119068988B (zh) * 2024-08-13 2025-04-15 北京国浩宇医疗科技有限公司 一种针对单细胞表达谱的智能化异常检测系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199579A1 (en) * 2018-04-09 2019-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107863D0 (en) * 2011-05-11 2011-06-22 Olink Ab Method and product
US10138509B2 (en) * 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
CN108474022A (zh) * 2015-11-03 2018-08-31 哈佛学院董事及会员团体 用于包含三维核酸的基质容积成像的设备和方法
HK1254531A1 (zh) * 2015-12-02 2019-07-19 Clearlight Diagnostics Llc 用於癌症检测和监测肿瘤组织样品的制备和分析方法
JP6811843B2 (ja) * 2016-08-19 2021-01-13 アリゾナ・ボード・オブ・リジェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシィティ 個々の細胞から対合ｍＲＮＡを捕捉及びシーケンスするためのボウタイ状バーコードの油乳化剤の大量合成
US20180208975A1 (en) * 2017-01-20 2018-07-26 Merck Sharp & Dohme Corp. Assay for simultaneous genomic and proteomic analysis
KR20220100589A (ko) * 2019-10-18 2022-07-15 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 임상 및 산업 규모의 온전한 조직 시퀀싱
EP4107285B1 (en) * 2020-02-21 2024-10-09 10X Genomics, Inc. Methods and compositions for integrated in situ spatial assay
US12060603B2 (en) * 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
CN114854838A (zh) * 2021-02-04 2022-08-05 美天施生物科技有限两合公司 结合靶向RNA或cDNA体外测序与原位测序的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199579A1 (en) * 2018-04-09 2019-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing

Also Published As

Publication number Publication date
AU2022281407A1 (en) 2023-11-30
US20240376530A1 (en) 2024-11-14
EP4644569A3 (en) 2026-01-07
EP4347878A1 (en) 2024-04-10
CA3219339A1 (en) 2022-12-01
CN117813395A (zh) 2024-04-02
WO2022251586A1 (en) 2022-12-01
KR20240014486A (ko) 2024-02-01
IL308570A (en) 2024-01-01
EP4644569A2 (en) 2025-11-05
EP4347878B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
EP4347878B1 (en) Co-mapping transcriptional states and protein histology
Phan et al. A myelin-related transcriptomic profile is shared by Pitt–Hopkins syndrome models and human autism spectrum disorder
Utz et al. Early fate defines microglia and non-parenchymal brain macrophage development
Duy et al. Impaired neurogenesis alters brain biomechanics in a neuroprogenitor-based genetic subtype of congenital hydrocephalus
Barrenschee et al. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson’s disease
Adua et al. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
Tranchevent et al. Systems level analysis of sex-dependent gene expression changes in Parkinson’s disease
JP2024529290A (ja) Ｒｎａの翻訳状態の単一細胞プロファイリング
US20210164051A1 (en) Methods of detection and analysis of nucleic acid in neural-derived exosomes
US20190085394A1 (en) Refining diagnosis and treatment of complex multi-symptom neurological disorders
Piras et al. Association of AEBP1 and NRN1 RNA expression with Alzheimer’s disease and neurofibrillary tangle density in middle temporal gyrus
Epstein et al. Subventricular zone stem cell niche injury is associated with intestinal perforation in preterm infants and predicts future motor impairment
Gaunt et al. Cytokine enrichment in deep cerebellar nuclei is contributed by multiple glial populations and linked to reduced amyloid plaque pathology
Demenego et al. Neurodevelopmental origins of structural and psychomotor defects in CXCR4-linked primary immunodeficiency
Crociara et al. Cellular and molecular characterization of multipolar Map5-expressing cells: a subset of newly generated, stage-specific parenchymal cells in the mammalian central nervous system
Wang et al. Prostaglandin E2-driven dedifferentiation of Schwann cells leads to perineural invasion in pancreatic ductal adenocarcinoma
EP4480478A1 (en) Screening method and therapeutic agent for mental disorder
CN108588214A (zh) 联合Aβ和D-gal构建的AD模型鼠海马区基因表达差异谱及其测定方法和应用
Lu et al. Single-cell transcriptomics reveals ependymal subtypes related to cytoskeleton dynamics as the core driver of syringomyelia pathological development
Fenu et al. Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration
Ehrenberg et al. Mislocalization and clearance of neuronal Rhes as a novel hallmark of tauopathies
Gallotti Validating advanced MRI features as surrogate biomarkers of the molecular subgroups of glioblastoma by exploiting patient-specific cancer stem cell (CSC)-based animal models.
Scholl et al. Neurite Outgrowth Inhibitor (NogoA) Is Upregulated in White Matter Lesions of Complex Cortical Malformations
Martín Integration of multiplex imaging, machine learning and single cell transcriptomic analyses in the characterization of focal cortical dysplasia and other malformations of cortical development
Duan et al. Spatial profiling of neuro-immune interactions in gastroenteropancreatic NETs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260521